Indeed, targeting the CCL2-CCR2 axis is being evaluated for therapy of breast cancer, although recent findings suggest that modulation of this pathway may result in deleterious unintended consequences in patients (Bonapace et al., 2014). This evidence concerns the gene CCR2 and breast cancer.